2017
Sex differences in the interacting roles of impulsivity and positive alcohol expectancy in problem drinking: A structural brain imaging study
Ide JS, Zhornitsky S, Hu S, Zhang S, Krystal JH, Li CR. Sex differences in the interacting roles of impulsivity and positive alcohol expectancy in problem drinking: A structural brain imaging study. NeuroImage Clinical 2017, 14: 750-759. PMID: 28413777, PMCID: PMC5385596, DOI: 10.1016/j.nicl.2017.03.015.Peer-Reviewed Original ResearchConceptsPositive alcohol expectanciesGray matter volumeAlcohol expectanciesAlcohol Use Disorders Identification TestSocial drinkersNon-dependent social drinkersProblem drinkingRole of impulsivityBrain imaging studiesRight posterior insulaSex differencesStructural brain imagingStructural brain imaging studiesNeural basisDisorders Identification TestBarratt impulsivityPsychological factorsImpulsivityMediation analysisPosterior insulaDependent individualsRisk factorsAlcohol misuseLinear modelingGeneral linear modeling
2011
Trajectories of Depression Severity in Clinical Trials of Duloxetine: Insights Into Antidepressant and Placebo Responses
Gueorguieva R, Mallinckrodt C, Krystal JH. Trajectories of Depression Severity in Clinical Trials of Duloxetine: Insights Into Antidepressant and Placebo Responses. JAMA Psychiatry 2011, 68: 1227-1237. PMID: 22147842, PMCID: PMC3339151, DOI: 10.1001/archgenpsychiatry.2011.132.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsData Interpretation, StatisticalDepressive Disorder, MajorDouble-Blind MethodDuloxetine HydrochlorideFemaleHumansLinear ModelsMalePatient DropoutsPlacebo EffectPsychiatric Status Rating ScalesRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexThiophenesTreatment OutcomeConceptsSelective serotonin reuptake inhibitorsPlacebo-treated patientsComparator selective serotonin reuptake inhibitorsHAM-D scoresClinical trialsAntidepressant treatmentPlacebo responseMajor depressionDouble-blind clinical trialHigh placebo response rateSerotonergic antidepressant treatmentPlacebo response ratesSerotonin reuptake inhibitorsAntidepressant nonrespondersPlacebo armMost patientsAntidepressant respondersMedication risksReuptake inhibitorsSerotonergic antidepressantsResponder statusTreatment responseClinical trajectoriesDepression scoresDepression severity
2010
Decreased Beta2*‐nicotinic acetylcholine receptor availability after chronic ethanol exposure in nonhuman primates
Cosgrove KP, Kloczynski T, Bois F, Pittman B, Tamagnan G, Seibyl JP, Krystal JH, Staley JK. Decreased Beta2*‐nicotinic acetylcholine receptor availability after chronic ethanol exposure in nonhuman primates. Synapse 2010, 64: 729-732. PMID: 20340174, PMCID: PMC2904861, DOI: 10.1002/syn.20795.Peer-Reviewed Original ResearchConceptsChronic ethanol consumptionEthanol consumptionAlcohol consumptionNicotinic acetylcholine receptor availabilityAverage daily ethanol consumptionChronic ethanol exposureDaily ethanol consumptionEthanol-induced changesNicotinic acetylcholine receptorsSelf-administer ethanolIA-85380H withdrawalEthanol exposureReceptor availabilityAcetylcholine receptorsParietal cortexMale animalsTotal gramsBaselinePercent decreasePersistent changesWithdrawalMidbrainCortexAnimalsWorking Memory Overload: Fronto-Limbic Interactions and Effects on Subsequent Working Memory Function
Yun RJ, Krystal JH, Mathalon DH. Working Memory Overload: Fronto-Limbic Interactions and Effects on Subsequent Working Memory Function. Brain Imaging And Behavior 2010, 4: 96-108. PMID: 20503117, PMCID: PMC2854358, DOI: 10.1007/s11682-010-9089-9.Peer-Reviewed Original ResearchConceptsMemory systemAmygdala-prefrontal interactionsSubsequent cognitive performanceWorking Memory FunctionFunctional magnetic resonanceDorsolateral prefrontal cortexMemory taskCognitive functioningNegative affectAmygdala activationCognitive performanceTask performanceCognitive overloadNeural effectsPrefrontal cortexMemory functionPerformance accuracySubsequent functioningSeparate factorsBrain regionsPerformance declineReduced activationFunctioningInverse couplingOverload effect
2007
Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study
Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH, Group T. Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study. Alcohol Clinical And Experimental Research 2007, 31: 555-563. PMID: 17374034, DOI: 10.1111/j.1530-0277.2007.00339.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismConfidence IntervalsDNADouble-Blind MethodExonsFemaleGenetic VariationGenotypeHumansLinear ModelsLogistic ModelsMaleMiddle AgedNaltrexoneNarcotic AntagonistsOdds RatioProportional Hazards ModelsPsychiatric Status Rating ScalesReceptors, Opioid, deltaReceptors, Opioid, kappaReceptors, Opioid, muSmokingTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsAlcohol dependenceOpioid receptorsTreatment responseVA Cooperative StudyRate of relapsePredictors of responseAlcohol-dependent male subjectsMu-opioid receptorsKappa-opioid receptorsCourse of treatmentShort-term treatmentReceptor gene variantsOpioid receptor geneAsn40Asp polymorphismAvailable medicationsNaltrexone treatmentSpecific pharmacotherapyPretreatment numberDrug naltrexoneNaltrexoneMale subjectsCooperative StudyRelapseHeavy drinkingIndividual single nucleotide polymorphisms
2006
Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive Symptoms
Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH. Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive Symptoms. Biological Psychiatry 2006, 61: 822-825. PMID: 17141740, PMCID: PMC2754299, DOI: 10.1016/j.biopsych.2006.08.037.Peer-Reviewed Original ResearchConceptsHamilton Depression Rating ScaleHamilton Anxiety Rating ScaleTreatment-resistant depressionMajor depressive disorderHARS scoresRating ScaleExcessive glutamatergic neurotransmissionEffects of riluzoleDepression Rating ScaleResidual depressive symptomsAnxiety Rating ScaleRiluzole efficacyMedication regimenAugmentation therapyContinuation phaseAntidepressant activityGlutamate neurotransmissionGlutamatergic neurotransmissionDepressive disorderAnxiolytic effectsDepressive symptomsRiluzolePatientsFirst weekLinear mixed models